[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-cognitive-impairment":643},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,224,0,25,[9,51,78,100,113,140,165,190,210,247,279,309,333,355,390,412,436,458,480,509,541,562,578,602,619],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100053654",false,"NCT04601038","Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)","Phase II Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)","CORT-X","Individuals must meet criteria for mild cognitive impairment due to Alzheimer's disease according to National Institute on Aging (NIA)\u002FAlzheimer's Association recommendations OR be cognitively normal based on clinical and cognitive assessment in the Enrollment Visit and have at least one of the following risk factors for AD:\n\n* Known to have at least 1 apolipoprotein E (APOE) ε4 allele;\n* Subjective cognitive concerns with a T score \\\u003C 40 on the Multifactorial Memory Questionnaire Satisfaction Scale;\n* A first-degree relative with dementia.\n\nInclusion Criteria for all subjects:\n\n* At least 55 years of age;\n* Body mass index \\>17 and \\\u003C30;\n* Post-menopausal (if female)\n* Non-smoker;\n* Availability of a study partner who has frequent contact with the subject (10+ hours\u002Fweek in person and by telephone), and is able to provide an independent evaluation of functioning;\n* Fluent English speaker;\n* Good general health with no disease expected to interfere with the study;\n* Willing and able to participate for the duration of the study.\n\nExclusion Criteria for all subjects:\n\n* Participation in a therapeutic clinical trial at any time during the study;\n* Abnormal corrected QT interval using Bazett's formula (QTcB; defined as \\> 450 ms for men and \\> 470 ms for women) as determined on ECG;\n* Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities, including lacunes in critical memory structures including the hippocampus and parahippocampal cortex;\n* Bipolar disorder within the past 1 year;\n* History of alcohol or drug dependence;\n* Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol;\n* General surgery within the last 3 months;\n* Sensory impairment (poor vision or hearing) significant enough to interfere with ability to provide valid cognitive test data;\n* Treatment within the last six months with neuroleptics, sedative hypnotics, or glucocorticoids;\n* Treatment within the last six months with medications metabolized by the CYP2C9 or CYP2C19 enzymes, most notably clopidogrel and proton pump inhibitors;\n* Concurrent use of a CYP3A inhibitor, including grapefruit juice, and St. John's Wort;\n* Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the PI.",true,"ALL","55 Years",{"count":21,"type":22},52,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","CORT-X will examine if mitigation of stress-mediated pathogenesis of Alzheimer's disease (AD) is a feasible target for intervention in individuals at risk for this disease. This single-site (Baltimore, Maryland) phase II clinical trial is a 2-week, randomized, placebo-controlled crossover study of the effects of the selective glucocorticoid receptor antagonist, CORT108297, on cognitive test performance in 26 individuals with mild cognitive impairment (MCI) due to AD and in 26 cognitively normal individuals with an increased risk for AD due to family history, genetics, and\u002For subjective memory complaints. All subjects will participate in a brief stressor (public speaking and mental arithmetic) and provide saliva samples so investigators can measure stress hormone response. Then, following 2 weeks of treatment with placebo or CORT108297, in counterbalanced order, participants will complete cognitive tests assessing memory and executive function. All study participants will receive CORT108297 and placebo over the course of this 10-week trial that requires 6 in-person study visits. The primary aims will compare the effects of CORT108297 to placebo on cognitive test performance in individuals with MCI due to AD and in individuals at risk for AD, and describe the side effects of CORT108297 in study participants. Secondary aims will identify subject characteristics that predict positive response to study drug.",[28,29,30],"Mild Cognitive Impairment","Alzheimer Disease","Memory Impairment",[32,33,34,35,36,37],"Stress","Memory loss","Dementia","Alzheimer's disease","Cognitive","Impairment","RECRUITING","2026-07-10",{"date":41,"type":42},"2026-07-13","ACTUAL",{"date":44,"type":42},"2021-06-28",{"date":46,"type":22},"2028-01-01",{"name":48,"class":49},"Johns Hopkins University","OTHER",1,{"id":52,"slug":4,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100054007","NCT07169630","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)","* INCLUSION CRITERIA:\n\nParticipants will be referred by a physician with the suspected diagnosis of AD or MCI. However, the PI of this protocol will provide the final diagnosis. For this reason, this protocol will have just one consent form for participants suspected of having either AD or MCI.\n\nAD and MCI Study Groups:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n* Have been diagnosed by a neurologist or psychiatrist with MCI or AD.\n* Be in good general health as evidenced by medical history and physical examination.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nHealthy Volunteers:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Able to provide informed consent.\n* Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth the study groups will be excluded if they meet any of the following criteria:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* Participants should not have taken non-steroidal anti-inflammatory drugs (NSAIDs) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n* Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n* Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n* Are unable to travel to the NIH.\n* Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n* Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the volunteer and\u002For caregiver during the screening visit.\n* Participants must not have substance use disorder or alcohol use disorder.\n* Participants should not be under treatment or previously treated with an amyloid antibody such as lecanemab.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n* Pregnancy or breast feeding.\n* HIV infection.\n* Non-English speaking participants.\n\nExclusion of Children:\n\nInclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit.\n\nExclusion of Pregnant or Breastfeeding Women:\n\nPregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will not require contraception for this protocol to allow participants autonomy in medical decision-making. However, while we will not require contraception for woman of childbearing potential, we will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant\n\nExclusion of Participants who are HIV Positive:\n\nPersons with HIV infection are excluded because HIV infection itself may change cAMP signaling.\n\nExclusion of Non-English-Speaking Participants:\n\nNon-English-speaking participants will be excluded from participation in this study because neuropsychological testing is required by this protocol. This testing, which is critical for interpreting study results, has not been validated in other languages or when using a translator.","50 Years","100 Years",{"count":60,"type":22},90,[62],"PHASE1","Background:\n\nAbout 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI.\n\nObjective:\n\nTo test whether medical imaging using a new radiotracer (\\[18F\\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI.\n\nEligibility:\n\nPeople aged 50 years and older with AD or MCI. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have up to 5 clinic visits with 3 imaging scans of the brain.\n\nThey will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory.\n\nParticipants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each.\n\nParticipants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....",[65,28,66],"Alzheimer s Disease","Healthy",[68,69],"18F-PF-06445974","PET Imaging",{"date":41,"type":42},{"date":72,"type":22},"2026-07-16",{"date":74,"type":22},"2030-04-11",{"name":76,"class":77},"National Institute of Mental Health (NIMH)","NIH",{"id":79,"slug":4,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":50},"100053364","NCT04765137","Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)","Targeting Cerebrovascular Reactivity for Precision Medicine: Pilot Trial of Atorvastatin","Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors:\n\n* MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.\n* Memory, processing speed, executive function, language - cognitive scores \\> 1.5 standard deviations below age-education norms.\n* Not demented by history.\n* Not taking statins currently or in the last 6 months.\n* Cognitive\u002Ffunctional impairment not likely due to another neurological disease or delirium.\n\nExclusion Criteria:\n\n* Taking a statin currently or have taken a statin in the last 6 months.\n* Contraindications to taking a statin.\n* Transplant patient taking cyclosporine.\n* Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).\n* Diagnosis of dementia by history.\n* Current diagnosis of substance abuse.\n* History of stroke or myocardial infarction in past 6 months.\n* History of HIV.","60 Years","95 Years",{"count":87,"type":22},20,[25],"The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.",[28],[92],"Cerebral Vascular Reactivity","2026-07-09",{"date":41,"type":42},{"date":96,"type":42},"2021-05-21",{"date":98,"type":22},"2027-12-31",{"name":48,"class":49},{"id":101,"slug":4,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":63,"conditions":104,"keywords":105,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":112,"locationsCount":50},"100605983",{"count":60,"type":22},[62],[65,28,66],[68,69],"2026-07-01",{"date":108,"type":42},"2026-07-02",{"date":110,"type":22},"2026-07-07",{"date":74,"type":22},{"name":76,"class":77},{"id":114,"slug":4,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":17,"sex":18,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":50},"100392965","NCT04396873","PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","* INCLUSION CRITERIA:\n\nPatients: In order to be eligible to participate in this study, patients must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n3. Have been diagnosed by a neurologist or psychiatrist with MCI, ALS, PD, or an adult onset neurodegenerative dementia, such as AD (including amyloid negative subjects), FTD, corticobasal syndrome, or Huntington s disease.\n4. Be in good general health as evidenced by medical history and physical examination.\n5. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n6. Agree to adhere to the lifestyle considerations.\n\nHealthy volunteers: In order to be eligible to participate in this study, healthy volunteer subjects must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Female participants of childbearing potential must be using a medically acceptable means of contraception\n3. Able provide informed consent.\n4. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n5. Be enrolled in 01-M-0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17-M-0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies\n6. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n7. Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth patients and healthy volunteers who meet any of the following criteria will be excluded from participation in this study:\n\n1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level \\>1.3 mg\u002FdL\n2. Subjects should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAID) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n3. Contraindications to ketoprofen, such as hypersensitivity to ketoprofen or history of upper or lower gastrointestinal bleeding.\n4. Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n5. Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n6. Are unable to travel to the NIH.\n7. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n8. Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the patient and\u002For caregiver during the screening visit.\n9. Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life.\n10. Participants should not be under treatment with Aduhelm, nor should they have been treated in the past.\n11. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n12. Pregnancy\n13. HIV infection\n14. Be NIMH staff or an NIH employee who is a subordinate\u002Frelative\u002Fco-worker of the investigators.","18 Years","99 Years",{"count":122,"type":22},184,[62],"Background:\n\nAbout 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.\n\nObjective:\n\nTo learn whether COX-1 and\u002For COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.\n\nEligibility:\n\nAdults age 18 years and older in good general health who have an adult-onset neurodegenerative dementia, such as AD, FTD, corticobasal syndrome, Huntington s disease, or MCI, ALS and healthy adult volunteers enrolled in protocols 01-M-0254 or 17-M-0181.\n\nDesign:\n\nParticipants will be screened with medical history, physical exam with vital signs, and lab tests. They will have a neuropsychological testing. Their heart function will be measured.\n\nParticipants will have a magnetic resonance imaging (MRI) scan. The MRI scanner is a metal tube surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the tube. The machine makes noise. Participants will get earplugs.\n\nParticipants will have 2 PET scans. They will be injected with the study drugs through an intravenous catheter placed in an arm vein. The PET scanner is shaped like a doughnut. Participants will lie on a bed that slides in and out of the scanner. A plastic mask will be molded to their head to keep them from moving. A thin plastic tube will be put into an artery at the wrist or elbow crease area. This will be used to draw blood during the scan.\n\nParticipants will have 2-5 study visits. Participation lasts 1 week to 4 months, depending on scheduling.",[126,34,127,128,28],"Parkinson's Disease","Alzheimer's Disease","ALS",[69,130,131,34,132,128,133],"PD","Inflammation","Cyclooxygenase-2","MCI",{"date":108,"type":42},{"date":136,"type":42},"2021-08-17",{"date":138,"type":22},"2030-10-03",{"name":76,"class":77},{"id":141,"slug":4,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":18,"minAge":147,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":50},"100611670","NCT07243600","Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment","Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment (INHANCE-MCI)","INHANCE-MCI","Inclusion Criteria:\n\n1. Potential participant must be 65 years or older at the time of study screening.\n2. Potential participant must have MCI as defined by:\n\n   * Total score between 18-26 inclusive on the Montreal Cognitive Assessment (MoCA)\n   * Cognitive concern by participant, informant, or clinician and evidence of preserved functional abilities as defined as a Clinical Dementia Rating (CDR) of 0.5 with a memory score of 0.5 or 1.\n3. Potential participant must have a study partner\u002Finformant defined as any acquaintance (e.g., family member, friend, neighbor, clinician) who has regular (at least monthly) interactions (in person or remote) with the participant.\n4. If potential participant reports use of medications typically prescribed for dementia such as, but not limited to, Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, Aducanumab, Leqembi or Lecanemab, Donanemab, the dose must be stable for at least 12 weeks prior to study enrollment.\n5. Potential participant must demonstrate adequate decisional capacity, in the judgment of the investigator, and capable of to making an informed decision regarding their participation in this research study.\n6. Potential participant must be likely able to complete all study activities and outcome measures in the judgment of the investigator.\n7. Potential participant must have the visual, auditory, and motors capacity to use the computerized intervention in the judgment of the investigator.\n8. Potential participant must be able to communicate in either English or French.\n\nExclusion Criteria:\n\n1. Potential participant has an existing diagnosis of major neurocognitive disorder at screening (DSM-IV).\n2. Potential participant who answered 'yes' to question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS or 'yes' to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on the C-SSRS \"Suicidal Behavior\" if the ideation or behavior occurred within 2 months from Participant's date of consent (as recommended by the FDA for treatment trials.)\n3. Potential participant scores \\>10 on the Geriatric Depression Scale - Short Form (GDS-SF).\n4. Potential participant has previously completed 10 or more hours of the computerized cognitive intervention program manufactured by Posit Science.\n5. Potential participant is participating in a concurrent clinical trial (involving an investigational pharmaceutical, behavioral treatment, medical device or other) that, in the judgment of the investigator, could affect the outcome of this study.\n6. Potential participant is pregnant or breastfeeding.\n7. Potential participant has claustrophobia or implantation with any medical devices above the waist that may concentrate radio frequency fields or have other medical issues that may frustrate participation in MRI\u002FPET imaging procedures.\n8. Potential participant has a history of large vessel stroke with significant residual motor or cognitive impairment.\n9. Potential participant has a history of moderate to severe traumatic brain injury with residual cognitive symptoms.\n10. Potential participant has a history of brain tumor.\n11. Potential participant has a congestive heart failure diagnosis.\n12. Potential participant has a primary diagnosis of idiopathic Parkinson's disease.\n13. Potential participant has multiple sclerosis or Amyotrophic lateral sclerosis diagnosis.\n14. Potential participant has evidence of a non-neurodegenerative neurological disorder that would interfere with the ability to carry out study activities.\n15. Potential participant has has evidence of any other unstable medical conditions that would interfere with the ability to carry out study activities or cause fluctuations in cognition (for example, but not limited to, unstable diabetes, chronic obstructive pulmonary disorder dependent on oxygen).\n16. Potential participant has any other clinically significant or unstable medical condition (for example, but not limited to, ongoing alcohol dependency or drug abuse, schizophrenia, psychosis) that in the investigator's opinion would interfere with the ability to carry out study activities.\n17. Potential participant is undergoing or plans to undergo surgery requiring anesthesia, chemotherapy, or radiation treatment in the six months following screening (can be rescreened and enrolled later).","65 Years",{"count":149,"type":22},84,[151],"NA","This study is a validation study to evaluate efficacy of two neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment (MCI).",[28],"NOT_YET_RECRUITING","2026-06-25",{"date":157,"type":42},"2026-06-29",{"date":159,"type":22},"2026-07-06",{"date":161,"type":22},"2027-05-31",{"name":163,"class":164},"Posit Science Corporation","INDUSTRY",{"id":166,"slug":4,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":18,"minAge":171,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":4},"100640516","NCT07579689","Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment","Effect of Gingko Biloba on the Blood Biomarkers in Mild Cognitive Impairment Patients With Alzheimer's Disease","Inclusion Criteria:\n\n* Age 20 years or older\n* Clinical Dementia Rating (CDR) score of 0.5\n* Patients clinically indicated for treatment with Ginkgo biloba extract\n\nExclusion Criteria:\n\n* Current use of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine.\n* Refusal to provide informed consent.\n* Presence of neurological or psychiatric conditions other than Alzheimer's disease that may affect cognitive function.\n* Known hypersensitivity to Ginkgo biloba extract or any of its components.\n* Pregnant women.\n* Genetic conditions associated with lactose intolerance, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n* Presence of bleeding disorders at screening, or requirement for continuous use of medications that may affect study drug efficacy (e.g., anticoagulants, antiplatelets, thrombolytics, peripheral vasodilators, PGE1 and its derivatives).\n* Any condition that, in the opinion of the investigator or study staff, makes the participant unsuitable for the study or unable to comply with study procedures.","20 Years",{"count":173,"type":22},120,[175],"PHASE4","This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment. Participants will be randomly assigned to receive either Ginkgo biloba or a placebo for 6 months. Changes in blood biomarkers, including p-tau217 and neurofilament light (NfL), as well as cognitive function, will be assessed to determine whether Ginkgo biloba may influence disease-related biological processes.",[28,127],[28,179,127,180],"Ginexin","Ginkgo Biloba Extract","2026-06-24",{"date":183,"type":42},"2026-06-26",{"date":185,"type":22},"2026-06",{"date":187,"type":22},"2028-12-31",{"name":189,"class":49},"Hanyang University",{"id":191,"slug":4,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":193,"conditions":199,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100542780","NCT06347315","Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)","COGNIKET-MCI Trial: A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center, Multi-country, Pivotal Trial to Study the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides (kMCT) and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment","Inclusion Criteria:\n\n1. Have read, understood, and signed the informed consent form (ICF).\n2. Be aged ≥60 years at the time of screening.\n3. Presence of acquired memory complaints with a duration of \\>3 months. Here we refer to memory\u002Fcognitive complaints in a broader sense that can involve other cognitive domains other than memory. (As reported by the participant or reliable trial informant. Trial informants can be a relative, spouse or domestic partner, or close friend who interacts closely enough with the participant to be able to respond to assessments\u002Fquestionnaires as needed.)\n4. Have a clinical diagnosis of MCI (with a clinical phenotype compatible with AD, insidious SVD \\[ie, no post-stroke cognitive impairment\\], or mixed AD\u002FSVD) according to the participating site, or referring center, aligned with international\u002Fnational standards for MCI diagnosis, and additionally informed by a minimum of one of the following objective criteria as assessed by components of the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery (CERAD NB):\n\n   1. Word list memory task: ≤19,\n   2. Word list recall: ≤5,\n   3. Fifteen-item subset of the Boston Naming Test (BNT): ≤13,\n   4. Constructional praxis recall: ≤7, or\n   5. Total CERAD score: ≤70.\n5. Full autonomy for daily living based on the Instrumental Activities of Daily Living (IADL)-Lawton scale:\n\n   1. Score for women: 8 or\n   2. Score for men: 5.\n6. Participants must have an available trial informant willing and able to attend the following 3 clinic visits with the participant: V1\u002Frandomization, V3\u002F12-month visit, and V4\u002F18-month visit.\n7. Participants must have a trial informant who in the opinion of the investigator, has contact with the trial participant for a sufficient number of hours per week (at least 2 hours per day and a minimum of 4 times per week).\n8. Participants and their trial informants have an adequate ability to read and write, as well as adequate vision and hearing for neuropsychological testing according to the investigator's judgment (corrective aids are allowed).\n9. CDR global score of 0 to 0.5 at screening.\n10. Sexually active females of childbearing potential (defined in further detail in Appendix 1 of the protocol) must practice 2 different highly effective methods of contraception with their heterosexual partner or remain abstinent during the trial and for 30 days after the last dose of nutritional formulation. If employing contraception, the highly effective methods of contraception detailed in Appendix 1 of the protocol must be followed.\n11. Females of childbearing potential must have a negative highly sensitive urine pregnancy test before randomization; a positive urine pregnancy test result must immediately be confirmed using a serum test.\n12. Participants able to satisfactorily comply with the protocol requirements.\n13. Participants willing and able to discontinue all prohibited concomitant medications to meet any protocol-required washout periods before and during the trial period (Section 9.6.1 of the protocol provides more details).\n\nExclusion Criteria:\n\n1. Diagnosis of a major neurocognitive disorder according to the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), or dementia according to the DSM-IV and the National Institute of Neurological and Communicative Diseases and Stroke\u002FAlzheimer's Disease and Related Disorders Association criteria at the time of enrollment.\n2. MCI related to past or recent concussion, COVID-19, or other specific etiologies (including neurodegenerative disease like Parkinson's disease, multiple sclerosis, Huntington's disease, Lewy-body disease, fronto temporal dementia), or associated with medication\u002Fsubstance use, per the investigator's judgment.\n3. A history of COVID-19 ≤120 days before screening or completion of a vaccination course against severe acute respiratory syndrome coronavirus 2 ≤14 days before screening. The vaccine received must have been authorized for emergency use or approved by the US Food and Drug Administration.\n4. Newly introduced, or change in dose, within the last 2 months before randomization, of physician-prescribed interventions or medications affecting cognition or AD (eg, acetylcholinesterase inhibitors, memantine, anti-amyloid-beta agents), or planned introduction of such medications during the trial.\n5. Participants who will likely require prohibited concomitant therapy during the trial based on the investigator's judgment.\n6. Known history of or ongoing alcohol or substance use disorder, based on medical history, that in the opinion of the investigator may conflict with the participant's participation.\n7. Participants who, in the opinion of the investigator, medical monitor, or sponsor should not participate in the trial.\n8. Symptoms suggestive of depression or anxiety according to the Hospital Anxiety and Depression Scale (HADS):\n\n   1. HADS-D ≥8 or\n   2. HADS-A ≥8.\n9. Known active HIV infection, COVID, hepatitis B, or hepatitis C based on medical history.\n10. Participants with epilepsy or a history of seizures, except for a single childhood febrile seizure, post-traumatic seizure, or alcohol withdrawal seizure.\n11. Participants considered to be in poor general health based on the investigator's judgment. Examples include participants who have recent clinically significant weight loss, chronic dehydration or hypovolemia, poor fluid or nutritional intake, or a recent clinically significant infection, as per the investigator's judgment.\n12. Cancer diagnosis in the past 2 years excluding select skin conditions considered to be fully treated (basal cell or squamous cell carcinomas of the skin) or early-stage cancer with excellent prognosis (eg, some prostate cancer conditions) according to the investigator's judgment.\n13. Renal disease (estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2) based on the investigator's assessment and historical data.\n14. Uncontrolled hypertension (systolic blood pressure \\>160 mm Hg, and\u002For diastolic blood pressure \\>100 mm Hg).\n15. Significant and uncontrolled thyroid disease according to the investigator's judgment.\n16. Any surgery or procedure requiring general anesthesia ≥3 hours, planned, or in the previous 3 months.\n17. Poorly regulated type 2 diabetes (HbA1c \\>9.0%), or type 2 diabetes that is currently treated with insulin, glucagon-like peptide-1 receptor analog (GLP-1 RA), or a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, or type 1 diabetes.\n18. Vitamin B12 deficiency per the investigator's judgment, or current use of B-vitamin supplementation \\>200% daily recommended value according to national standards.\n19. Very high or severe hypertriglyceridemia (≥886 mg\u002FdL or 10.0 mmol\u002FL).\n20. Participants who are unable to comply with protocol procedures in the opinion of the investigator (if an individual develops a major neurocognitive disorder during the course of the trial, the appropriateness for the individual to continue will be based on the investigator's judgment).\n21. Have a personal or hierarchical link with the research team members.\n22. Participant who is a shift worker that involves night shifts.\n23. Ongoing\u002Fplanned pregnancy or breastfeeding at screening (female participants who have a positive pregnancy test result before receiving nutritional formulation will be excluded).\n24. Participants who follow a ketogenic diet or other diet that is intended to influence ketone levels (eg, prolonged fasting, intermittent fasting, ketogenic meal replacement product regimens), or take ketone-, kMCT-, or coconut oil supplementation, or adhere to a diet that excludes milk product use (eg, vegan diet).\n25. Cow's milk protein allergy or intolerance, or other allergy or intolerance to any of the ingredients of the nutritional formulation (eg, medium chain acyl-CoA deficiency, or other fatty acid oxidation disorders).\n\nUS protocol specificities:\n\n4\\. Have MCI (with a clinical phenotype compatible with AD, insidious SVD \\[ie, no post-stroke cognitive impairment\\], or mixed AD\u002FSVD) according to the participating site or referring center, as aligned with the National Institute on Aging and the Alzheimer's Association or Mayo Clinic standards for MCI, and additionally informed by a minimum of one of the following objective criteria as assessed by components of the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery (CERADNB):\n\n1. Word list memory task: ≤19,\n2. Word list recall: ≤5,\n3. Fifteen-item subset of the Boston Naming Test (BNT): ≤13,\n4. Constructional praxis recall: ≤7, or\n5. Total CERAD score: ≤70.\n\n   6\\. Participants must have an available trial informant willing to attend the following 4 clinic visits with the participant: screening, V1\u002Frandomization, V3\u002F12-month visit, and V4\u002F18-month visit.\n\n   9\\. CDR global score of 0 at screening.\n\n   10\\. Sexually active females of childbearing potential must practice highly effective methods of contraception with their heterosexual partner (defined in further detail in Appendix 1 of the protocol) or remain abstinent during the trial and for 30 days after the last dose of nutritional formulation. If employing contraception, the highly effective methods of contraception detailed in Appendix 1 of the protocol must be followed.",{"count":197,"type":22},380,[151],[28],"2026-06-17",{"date":202,"type":42},"2026-06-18",{"date":204,"type":42},"2024-05-24",{"date":206,"type":22},"2027-12-15",{"name":208,"class":164},"Société des Produits Nestlé (SPN)",28,{"id":211,"slug":4,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":18,"minAge":217,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":50},"100642364","NCT07652931","Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns","AHEAD: AI-driven Brain Health for Early Alzheimer's Disease Detection in Individuals With Subjective Cognitive Decline","AHEAD","Inclusion Criteria:\n\n1. Diagnosis of Subjective Cognitive Decline (SCD) according to international diagnostic criteria (Jessen et al., 2014).\n2. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event.\n3. Normal age-, gender-, and education-adjusted performance on standardized cognitive tests used to classify mild cognitive impairment (MCI) or prodromal AD.\n4. Age greater than or equal to 40 years.\n5. Native Italian Speaker.\n6. Stable pharmacological treatment for at least 4 weeks prior to enrollment.\n7. Provision of oral and written informed consent to study participation.\n\nExclusion Criteria:\n\n1. Presence of MCI, prodromal AD, or dementia.\n2. Any major systemic, psychiatric, or neurological disturbance.\n3. Medical conditions or substance abuse that could interfere with cognition.\n4. Pacemaker and\u002For other implanted neurostimulation devices in the head\u002Fneck district.\n5. Contraindications to undergoing MRI examination.\n6. Brain damage at routine MRI, including extensive cerebrovascular disorders.\n7. Traumatic or surgical wounds that could determine a risk of infection at the site of non-invasive stimulation.\n8. Scalp alterations that could determine the spread of excessive current from the device.\n9. Known history of epilepsy (due to small risk of seizure induction from rTMS in epileptic patients).\n10. Denial of oral and written informed consent to study participation.","40 Years",{"count":219,"type":22},300,[151],"AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.\n\nThe study uses artificial intelligence (AI) to integrate multimodal data - including MRI, EEG, Optical Coherence Tomography (OCT), neuropsychological assessments, and plasma biomarkers - to identify individuals with underlying Alzheimer's disease (AD) biology and predict cognitive progression.\n\nOnly participants found to be AD plasma biomarker positive (SCD+) undergo longitudinal follow-up at 12 and 24 months. Participants classified as high risk additionally receive a 6-month personalized multidisciplinary intervention combining high-frequency transcranial magnetic stimulation (TMS), digital cognitive training, structured physical exercise, and targeted management of modifiable vascular and behavioral risk factors.",[223,29,28,224],"Subjective Cognitive Decline","Cognitive Decline",[223,35,226,227,228,229,230,231,232,233,234,235,236,237,238],"Artificial Intelligence","Transcranial Magnetic Stimulation","Plasma biomarkers","p-tau217","MRI","EEG","Optical Coherence Tomography","Cognitive Training","Physical Exercise","Brain Health","APOE","Machine Learning","Deep Learning","2026-06-11",{"date":200,"type":42},{"date":242,"type":22},"2026-08-01",{"date":244,"type":22},"2029-08-01",{"name":246,"class":49},"IRCCS San Raffaele",{"id":248,"slug":4,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":259,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":50},"100502446","NCT05822362","CBD for Individuals at Risk for Alzheimer's Disease","Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial","Inclusion Criteria:\n\n1. Must be between the ages of 55 - 85 and provide valid informed consent.\n2. Participant must receive a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation by a clinician, or have symptoms of Mild Cognitive Impairment as determined by the study physician.\n3. Functional Activities Questionnaire (FAQ) score of 8 or less and self-reported ability to function independently.\n4. Montreal Cognitive Assessment (MoCa) score is ≤ 25\n5. Participant must have a CDR score of .5 or 1 on the Clinical Dementia Rating scale (CDR), which includes an assessment of function and is often used to distinguish MCI from dementia. A score of 0.5 indicates mild cognitive impairment but not dementia and a score of 1 indicates mild-to-moderate cognitive impairment.\n6. Must have an informant that will be utilized over the course of the 24 week study (must be the same person for all CDR assessments completed via phone).\n7. Participant must pass a test of consent comprehension\n8. Must be interested in using CBD to help with cognitive function\n9. Must plan on living in the Denver metro area over the next 6 months\n10. Able to attend in-person visits at the study site\n\nExclusion Criteria:\n\n1. Any other central nervous system (CNS) disease that would be expected to affect cognition, Parkinson's disease, multiple sclerosis.\n2. History of brain injury resulting in current memory loss symptoms (e.g., concussion with significant loss of consciousness)\n3. Any significant systemic illness or unstable medical condition\n4. Current use of Parkinson's medications, antipsychotic medications, anti-seizure medications, or anticholinergic medications\n5. Current or lifetime diagnosis of a schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \\& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by the DSM-5-TR\n6. Participation in other clinical studies involving neuropsychological measures being collected more than one time per year.\n7. Reported use of other drugs (cocaine, opiates, methamphetamine, MDMA) in the past 60 days or test positive on a urine test for those drugs of abuse at baseline.\n8. Report using more than 150mg of cannabis edible products per week.\n9. Report using more than 7 grams of cannabis flower product (not including CBD) per week.\n10. Recent history of, or meets criteria for major depression with suicidal ideation.\n11. Reports use of medical CBD.\n12. Liver function enzymes (AST, ALT) that are greater than 2x normal.\n13. Currently taking medications known to be contraindicated with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide, clobazam, lamotrigine, valproate).\n14. Pregnant at the time of study enrollment or unwilling to use contraception through the duration of the study (if not yet post-menopausal)\n15. Individuals with potentially reversible causes of mild cognitive impairment (i.e., hypothyroidism, Vitamin B12 deficiency).","85 Years",{"count":255,"type":22},236,[25],"This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.",[28],[260,261,262,263,127,264,133,28,265,266,267,268,269,270],"Cognition","Cannabidiol","Aging","Memory","CBD","Cognitive decline","Healthy aging","Older adults","Brain","Cannabis","Marijuana",{"date":272,"type":42},"2026-06-15",{"date":274,"type":42},"2024-01-19",{"date":276,"type":22},"2029-04",{"name":278,"class":49},"University of Colorado, Denver",{"id":280,"slug":4,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":50},"100642408","NCT07602283","Music for Pain and Dementia","Neurophysiological and Neuroendocrinal Benefits of Music Based Interventions for Early Alzheimer's Patients and Their Caregivers","Music4Pain","Inclusion Criteria:\n\n* Clinical Dementia Rating 0.5 - 2\n* Be a person with or caregiver to a person with a diagnosis of early Alzheimer's Disease, mild dementia, and\u002For mild cognitive impairment (MCI) and chronic pain defined as non-cancer pain lasting \\>3 months that occurs most days and limits life or work activities OR Be a caregiver to a person with a diagnosis of early Alzheimer's Disease, mild dementia, and\u002For mild cognitive impairment (MCI) and chronic pain defined as non-cancer pain lasting \\>3 months that occurs most days and limits life or work activities\n* Able to provide informed consent\n* Willing to wear an EEG headset and heart rate monitoring devices\n* Willing to answer survey questions about topics related to the study\n* Willing to be audio \u002F video recorded\n* Willing to undergo QST, blood draw, heart rate data collection and cognitive testing\n\nExclusion Criteria:\n\n* Clinical Dementia Rating \\\u003C0.5 or \\> 2\n* Unable to provide informed consent\n* Endorsing suicidal ideation (SI), self-injurious behavior, or homicidal ideation (HI) above the threshold defined in the \"Risk Reduction and Safety Plan\"\n* Participating in another clinical trial studying AD and\u002For Dementia\n* Starting a new prescription medication in the last 4 weeks\n* Taking central nervous system acting medications that may interfere with study measurements as determined at PI discretion","80 Years",{"count":288,"type":22},60,[151],"This study aims to provide mechanistic insights into how group drumming as a music-based intervention (MBI) affects pain responses and nociceptive function in individuals with Alzheimer's Disease (AD), mild dementia or mild cognitive impairment (MCI). Heart rate (HR), heart rate variability (HRV), and brain activity will be measured during communal drumming with their dyadic partners and others. Brain activity, blood pressure, cognitive abilities, blood hormone levels, and static and dynamic pain will also be measured during sessions pre and post the 8-week community drum circle. Investigators will leverage various measurement techniques including, but not limited to, electroencephalography (EEG), quantitative sensory testing (QST), behavioral, surveys, and physiological monitoring to study the impact of group drumming on pain and brain activity in AD and inter-dyad synchrony.",[29,34,28,292,293],"Peer-bonded Caregiver","Caregiver",[295,231,296,297,298,299],"Live Music","EKG\u002FECG","Anxiety","Connectedness","Social Connection","2026-06-10",{"date":302,"type":42},"2026-06-12",{"date":304,"type":42},"2026-06-09",{"date":306,"type":22},"2028-02-01",{"name":308,"class":49},"Yale University",{"id":310,"slug":4,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":329,"leadSponsor":331,"locationsCount":50},"100643450","NCT07638748","Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment","Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment (VR-MCI)","(VR-MCI)","Inclusion Criteria:\n\n* Clinical diagnosis of MCI (MoCA 18-26) or self-reported subjective cognitive decline (SCD)\n* Capacity to provide informed consent\n* Able to provide own transportation to sessions\n* Speaks and understands English\n* Ambulatory\n\nExclusion Criteria:\n\n* Uncontrolled seizures or epilepsy\n* Severe psychiatric illness or active suicidality\n* Inability to follow instructions or tolerate VR (severe motion sickness)\n* Cognitive impairment as a result of a known cause (e.g., dementia, stroke, Traumatic Brain Injury (TBI), medications, etc.)\n* Any condition that the research team determines would interfere with safe participation","90 Years",{"count":318,"type":22},10,[151],"The purpose of this study is to demonstrate feasibility, usability, and acceptability of VR-based cognitive and physical rehabilitation, evaluate adherence, tolerability, and fidelity to the VR intervention and explore preliminary effectiveness of VR-based rehabilitation on cognitive, physical, and functional outcomes",[28,322],"Subjective Cognitive Decline (SCD)",[324,325,326],"Virtual Reality","Cognitive Rehabilitation","Physical Rehabilitation",{"date":300,"type":42},{"date":302,"type":22},{"date":330,"type":22},"2026-11-30",{"name":332,"class":49},"The University of Texas Health Science Center, Houston",{"id":334,"slug":4,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":18,"minAge":217,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":342,"briefSummary":343,"conditions":344,"keywords":346,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":353,"locationsCount":4},"100642760","NCT07642518","Transcutaneous Auricular Vagus Nerve Stimulation in Type 2 Diabetes With Mild Cognitive Impairment","Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Type 2 Diabetes and Mild Cognitive Impairment: A Single-Center, Randomized, Double-Blind, Sham-Controlled Clinical Trial","Inclusion Criteria:\n\n1. Type 2 diabetes mellitus\n2. Meets criteria for mild cognitive impairment\n3. Aged 40 to 75 years, with no gender restrictions\n4. HbA1c levels between 6.5% and 9.0%\n5. At least 6 years of formal education\n6. Able to cooperate with and complete all cognitive and functional assessments\n7. Right-handed\n8. Voluntary provision of written informed consent\n\nExclusion Criteria:\n\n1. Concomitant use of GLP-1 receptor agonists, Alzheimer's disease medications, anti-Parkinson's medications, antiepileptic drugs, or antipsychotic drugs within 3 months prior to screening\n2. Presence of dementia-related neurological disorders; current or history of clinically significant psychiatric disorders within the past 2 years (e.g., schizophrenia, bipolar disorder, major depressive disorder, generalized anxiety disorder, personality disorders)\n3. CNS diseases, including traumatic brain injury, intracranial hemorrhage, acute cerebral infarction, etc\n4. Severe sinusitis, nasal and sinus polyps, space-occupying lesions such as skull base or nasopharyngeal tumors; congenital diseases or history of trauma of the nose, maxillofacial region, or skull base that affect olfactory function; presence of upper respiratory tract infection symptoms (e.g., nasal congestion, rhinorrhea, fever) on the day of the MRI scan\n5. Acute complications of diabetes, including diabetic ketoacidosis, hyperglycemic hyperosmolar state, hypoglycemic coma, etc\n6. Severe impairment of major organ function (e.g., heart, liver, kidneys), including any of the following: ALT and\u002For AST \\> 3×ULN. eGFR \\\u003C 45 mL\u002Fmin\u002F1.72 m² (CKD-EPI). History of unstable angina, myocardial infarction, or NYHA Class II or higher heart failure within 3 months prior to screening\n7. Concurrent major illnesses, such as active or untreated malignancies, or malignancies in clinical remission for less than 5 years.\n8. Contraindications for MRI scans (e.g., implanted metallic prostheses, claustrophobia); presence of cardiac pacemakers or other implantable medical devices; severe infection or ulceration of the auricular skin\n9. Pregnant or lactating women\n10. History of alcohol abuse, defined as an average weekly alcohol consumption exceeding 21 units for males and 14 units for females (1 unit = 360 mL of beer, 150 mL of wine, or 45 mL of distilled spirits\u002Fliquor)\n11. Any other conditions or factors that, in the opinion of the investigator, may confound the efficacy or safety evaluation of the study, making the participant unsuitable for enrollment","75 Years",{"count":341,"type":22},38,[151],"This study is a 24-week, single-center, randomized, double-blind, sham-controlled, parallel-group clinical trial. A total of 38 patients with type 2 diabetes and mild cognitive impairment were enrolled and randomly assigned in a 1:1 ratio to either the treatment group (receiving active transcutaneous auricular vagus nerve stimulation) or the sham control group (receiving sham transcutaneous auricular vagus nerve stimulation). The primary objective of this study is to evaluate the potential disease-modifying effects of transcutaneous auricular vagus nerve stimulation on cognitive impairment in patients with type 2 diabetes.",[345,28],"Type 2 Diabetes",[345,28,347,348],"Cognitive Impairment","Transcutaneous Auricular Vagus Nerve Stimulation",{"date":239,"type":42},{"date":351,"type":22},"2026-05-20",{"date":98,"type":22},{"name":354,"class":49},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":356,"slug":4,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":18,"minAge":147,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":386,"leadSponsor":388,"locationsCount":50},"100621109","NCT07366346","Telehealth-Adapted Compensatory Training and Intervention for Cognition","Telehealth-Adapted Compensatory Training and Intervention for Cognition for People With Mild Cognitive Impairment","TACTIC","Inclusion Criteria:\n\n* 65 years of age or older, less than 85 years\n* Have the ability to speak and understand English\n* Time and willingness to commit to the completion of this study\n* Availability of a study partner (typically a relative, spouse, offspring, or roommate) for initial and post-intervention testing\n* A global Clinical Dementia Rating scale (CDR) score of 0.5 and cognitive performance of \\\u003C26 on the Montreal Cognitive Assessment (MoCA) or \\\u003C19 on the MoCA-BLIND for categorization of MCI, as determined in the screening appointment.\n\nExclusion Criteria:\n\n* Self-reported diagnosis of dementia or functional impairment that requires assistance\n* Recent changes in medications for memory (i.e., prescribed or changed medications for memory within 30 days)\n* Major psychiatric illness (schizophrenia, current substance dependence, or undertreated depression or anxiety), or 15-item Geriatric Depression Scale (GDS-15) score of eight or higher\n* Hearing, vision, or motor deficits that would interfere with standardized cognitive assessment or participation in study interventions: e.g., inability to hear through headphones (with or without hearing aids). If vision is corrected with lenses to appropriate levels, then participant will be eligible\n* No access to reliable, stable internet, OR\n* Current participation in another cognitive training program or treatment study.","84 Years",{"count":364,"type":22},100,[151],"The goal of this clinical trial is to develop a five-week virtual cognitive training intervention for people with Mild Cognitive Impairment (MCI) based off an existing eight-week intervention. The main question it aims to answer is:\n\n• Is five weeks of training as good as eight weeks in improving cognition, quality of life, daily functioning, and mood, and in reducing caregiver burden? Researchers will compare five weeks of cognitive training to eight weeks of training to see if the shorter version is as effective as the full training.\n\nParticipants will complete all activities virtually:\n\n* Complete a screening visit with a study partner (typically a family member, roommate, or close friend) to determine eligibility to participate in the study\n* Complete some tests of memory and thinking and some questionnaires\n* Attend weekly two-hour group cognitive training sessions with a trained group leader, for five or eight weeks\n* Redo the questionnaires and tests of memory and thinking immediately after completing the training, and three months after completing the training",[133,28,368],"Mild Cognitive Impairment (MCI)",[370,371,372,373,374,375,376,377,378,379,380,381],"cognitive training","compensatory cognitive training","mild cognitive impairment","cognitive decline","cognitive intervention","cognitive strategies","group intervention","everyday functioning","cognition","brain health","dementia prevention","dementia","2026-05-29",{"date":384,"type":42},"2026-06-03",{"date":382,"type":42},{"date":387,"type":22},"2027-08",{"name":389,"class":49},"University of Florida",{"id":391,"slug":4,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":316,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":397,"briefSummary":398,"conditions":399,"keywords":402,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":50},"100632336","NCT07512362","Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.","A Pilot Study to Assess the Effect of Adding 1 Infusion of Human Mesenchymal Stem Cells (hMSC) to Patients Treated With Anti-Amyloid Monoclonal Antibodies Who Are Suffering From Mild Cognitive Impairment or Mild Alzheimer's Disease.","Inclusion Criteria:\n\n* Adults 55-90 years at the time of signing consent\n* Patients diagnosed with Mild Cognitive Impairment or mild Dementia due to Alzheimer disease, receiving treatment with an FDA approved monoclonal antibody (Leqembi\u002FLecanemab or Kisunla\u002FDonanemab) for at least 6 months prior to the infusion visit.\n* MMSE score 20-26.\n* Patients must be able to consent.\n* Have a family member or friend (study partner) who has frequent and sufficient contact with the patient and is able to answer questions about the participant's daily activities to complete the ADCS-MCI-ADL. Completing this scale is required to assess the impact of the study intervention on cognitive function and daily living skills in this patient population. Having a study partner is a requirement of this study.\n\nExclusion Criteria:\n\n* Dementia other than AD\n* Patient with severe depression. Patients with controlled depression are allowed to participate.\n* Inability to independently provide informed consent is considered exclusionary per protocol requirements\n* Recent history of substance abuse\n* History of bleeding disorders, HIV, HCV or HBV\n* Recent history (within 3 years) of malignancies, except for treated basal cell, squamous carcinoma or melanoma in situ, prostate in situ, cervical carcinoma in situ.\n* Uncontrolled medical conditions (hypertension, diabetes, unstable angina or MI within 1 year prior to screening)\n* History of bleeding disorder\n* Currently receiving (or received within four weeks of screening) experimental agents for the treatment of Alzheimer's Disease or enrolled in clinical trials in the prior 3 months.\n* Be a transplant recipient or in any other active medical condition than in the opinion of the investigator may compromise the safety or compliance of the patient or preclude successful completion of the study\n* Be premenopausal",{"count":318,"type":22},[25],"The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.",[28,400,401],"Early Alzheimer's Disease","AD-MCI",[28,133,401,400],"2026-05-26",{"date":405,"type":42},"2026-05-28",{"date":407,"type":42},"2026-05-15",{"date":409,"type":22},"2028-06-15",{"name":411,"class":49},"Bernard (Barry) Baumel",{"id":413,"slug":4,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":435},"100440509","NCT05016219","Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients","Phase 2 - The Use of Rhythmic Light Therapy to Entrain Gamma Oscillations and the Circadian System in Patients With Alzheimer's Disease","Inclusion Criteria:\n\n* Participants must be diagnosed with mild cognitive impairment or mild Alzheimer's disease, as defined by a Montreal Cognitive Assessment score between 17 and 25;\n* Have sleep disturbance indicated by a score \\>5 on the Pittsburgh Sleep Quality Index\n* Participants must reside in their homes, independent living, or assisted living facilities\n\nExclusion Criteria:\n\n* Participants taking sleep medication\n* Residence in a skilled nursing facility or long-term care\n* Obstructing cataracts, macular degeneration, and blindness\n* Severe sleep apnea or restless leg syndrome\n* History of severe epilepsy",{"count":173,"type":22},[151],"Participants will randomly be placed into one of four groups and experience one of the four following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic light \\[RL\\]); (2) a placebo light with a random flicker (placebo condition for rhythmic light); (3) a light source that will stimulate the circadian system and provides a 40 Hz flicker (RL); or (4) a light source that will stimulate the circadian system and provides a random flicker (placebo condition for rhythmic light). Following a baseline week, participants will experience his\u002Fher assigned lighting condition for two hours in the morning for 8 weeks. After a 4-week washout period, a final round of assessments will be obtained. Study assessments (except for the Pittsburgh Sleep Quality Index and Montreal Cognitive Assessment) will be collected at the end of each week, for a total of 8 assessments.",[28],[423,424,425,426,427,260],"Light Treatment","Circadian Rhythms","Gamma Wave Entrainment","Rhythmic Light","Sleep",{"date":382,"type":42},{"date":430,"type":42},"2023-08-22",{"date":432,"type":22},"2027-07-31",{"name":434,"class":49},"Icahn School of Medicine at Mount Sinai",2,{"id":437,"slug":4,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":11,"sex":18,"minAge":119,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":445,"phases":4,"briefSummary":446,"conditions":447,"keywords":448,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":454,"leadSponsor":456,"locationsCount":50},"100620744","NCT07361601","Implementation of AIP Services for Older Adults With AD","Implementation of Aging in Place Services for Older Adults With Alzheimer's Disease","PYL-AIP","Inclusion Criteria - Current Cohort:\n\n1. Active participant in the 'Decision Making and Implementation of Aging-in-Place\u002FLong Term Care Plans among Older Adults' \\[R01AG058777\\] study;\n2. Age 65 years or older (older adult); age 18 years or older (caregiver)\n3. Speak English; and\n4. Pass UBACC (University of California, San Diego Brief Assessment of Capacity to Consent) cognitive assessment\n\nInclusion Criteria - Caregiver:\n\n1. Age 18 years or older;\n2. Speak English;\n3. Currently assist enrolled, older adult study participant with activities such as managing their health, and\u002For household activities (i.e., taking them to the doctor, housekeeping, meal prep, medication reminders); and\n4. Pass UBACC (University of California, San Diego Brief Assessment of Capacity to Consent) cognitive assessment",{"count":444,"type":22},285,"OBSERVATIONAL","This study will longitudinally follow a cohort of older adults to better understand how decisions about aging in place or transitioning to long-term care-and the implementation of those decisions-are influenced by age-related changes (e.g., cognition, health literacy, chronic conditions) and social supports (e.g., caregivers).",[29,28],[449,450],"Aging in place","Long term care planning","2026-05-21",{"date":403,"type":42},{"date":106,"type":22},{"date":455,"type":22},"2031-12-31",{"name":457,"class":49},"Northwestern University",{"id":459,"slug":4,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":468,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":50},"100558213","NCT06548191","TREAD: Time Restricted Eating Intervention for Alzheimer's Disease","TREAD","Provision of signed and dated informed consent form. Stated willingness to comply with all study procedures and availability for the duration of the study.\n\nInclusion criteria\n\n1. Persons, aged ≥60 years\n2. In good general health as evidenced by medical history or diagnosed with clinical diagnosis of MCI\u002FAD: meeting research consensus criteria for probable MCI or dementia due to AD, requiring positive amyloid biomarkers in brain or cerebrospinal fluid (CSF) obtained at their regular point of care or study referral no longer than 3 months prior to screening.\n3. Ability and willingness to complete cognitive evaluations, blood draw, actigraphy monitoring and to record fasting times daily.\n4. Daily night fasting \\\u003C12h at baseline. Ability and willingness to follow an eating protocol of prolonged night fasting for 14 h\n5. For cognitively normal living partners in the dyads group, scores \\>26 in the Montreal Cognitive Assessment (MoCA) test administered at screening.\n\nExclusion Criteria:\n\n1. Clinical diagnosis with a neurodegenerative condition other than MCI\u002FAD.\n2. Presenting cognitive impairment not due to AD.\n3. Clinical diagnoses of diabetes.\n4. Actively using insulin in the past 6 months.\n5. Started a new medication (or changed doses) indicated for the treatment of MCI\u002FAD in the last three months prior to enrollment.\n6. Currently taking any medication known to affect appetite, inlcuding but not limited to GLP-1 agonists.\n7. Any history of disordered eating, including difficulty swallowing and refusal to eat.\n8. Currently engaged in shift work.\n9. In treatment with another investigational drug.\n10. Body Mass Index (BMI) \\\u003C20. or \\>35",{"count":288,"type":22},[62],"The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults. The main questions it aims to answer are:\n\n* Does prolonged nightly fasting of 14 h can reduce markers of AD pathology and aging and reduce cognitive and sleep alterations in MCI and AD patients?\n* Can patients with MCI and early \u002Fmoderate AD sustain time-restricted eating for 3 to 6 months? Researchers will compare participants who fast for 14 h per night during 3 months to those who fast for less than 12 h\u002Fnight. Researchers will also compare participants that fast for 3 months to those who fast during 6 months, to determine the effective duration of the intervention. Finally, researchers will evaluate whether following the time-restricted eating diet alongside a partner actively following the same diet, will increase adherence to the protocol compared to subjects that fast alone.\n\nParticipants will:\n\n* Fast for 14 h a night (stop eating at 8 pm and start eating the following morning at 10 am) for 3 or 6 months\n* Visit the clinic three times (at the beginning of the study, 6 and 12 months later)\n* Provide blood samples and take a cognitive test during clinic visits\n* Keep a diary (or use an app on a smart phone) to record time of eating\n* Wear an activity tracker watch",[28,29,127],[469,470,471,28,29,424,260,472],"Time-Restricted Eating","Intermittent Fasting","Prolonged Nightly Fasting","Neuropathology",{"date":403,"type":42},{"date":475,"type":42},"2025-04-23",{"date":477,"type":22},"2027-06-30",{"name":479,"class":49},"University of California, San Diego",{"id":481,"slug":4,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":339,"enrollmentInfo":486,"targetDuration":4,"studyType":23,"phases":488,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":50},"100588009","NCT06935812","Comparison of the Effects of Bimanual, Finger and VR Exercises in PwMCI","Comparison of the Effects of Bimanual, Finger and Virtual Reality Exercises in Individuals With Mild Cognitive Impairment - Randomized Controlled Study","Inclusion Criteria:\n\n* Participants who are between 50-75 years of age\n* Individuals diagnosed with MCI by a geriatrician according to DSM-5 criteria,\n* Who has the Montreal Cognitive Assessment score between 13-26,\n* Who has the Quick Mild Cognitive Impairment screen score between 48-67,\n* Who has Instrumental Activities of Daily Living Scale score ≥6\u002F8,\n* Who says yes to \"Do you have a memory problem?\" question,\n* Who can walk independently without using any walking aids\n\nExclusion Criteria:\n\n* Participants who have any musculoskeletal disorders that may cause balance and gait disorders,\n* Who have central or peripheral neurological diseases (eg. stroke, Parkinson's disease or polyneuropathies),\n* Who are using psychiatric drugs that may affect psychiatric disease and\u002For cognitive performance (Using nonsteroidal anti-inflammatory drugs more than three times a week, which may affect cognitive functions, using gingko biloba and antioxidant supplements (for example, coenzyme Q10 and alpha-lipoic acid)),\n* Who has daltonism and\n* Who attends any exercise program last 6 months will not be included in this study.",{"count":487,"type":22},106,[151],"Mild Cognitive Impairment (MCI) is defined as an impairment in a single cognitive function, usually memory, other than normal cognitive decline with age, that does not fulfil dementia criteria. Finger movements have been shown to stimulate the sensory-motor and cognitive parts of the cerebral cortex, as well as the supplementary motor area, Broca's area, premotor cortex, and prefrontal cortex, all of which contribute to movement skills. Asymmetrical hand and finger movements done concurrently were proven to improve cognitive processes and cerebral blood flow more than movements performed with one hand.",[28],[492,493,324,494,495,496,497,498,499],"Finger Exercise","Bimanual Exercise","Processing Speed","Cognitive Functions","Walking Speed","Gross Motor Skills","Fine Motor Skills","Dual Task","2026-05-17",{"date":502,"type":42},"2026-05-19",{"date":504,"type":42},"2025-04-29",{"date":506,"type":22},"2026-09-24",{"name":508,"class":49},"Eastern Mediterranean University",{"id":510,"slug":4,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":286,"enrollmentInfo":516,"targetDuration":4,"studyType":23,"phases":518,"briefSummary":519,"conditions":520,"keywords":526,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":539,"locationsCount":50},"100620930","NCT07364019","The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia","The Brain Health PRO Online Risk Factor Reduction Study for The Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia","BHPROOF","Inclusion Criteria:\n\n* Completion and documentation of the electronic Informed Consent Process (from the participant)\n* Sufficient proficiency in English or French to undergo online assessments and participate in an online educational program.\n* Technical ability to participate in an online educational program and remote assessments (i.e., regularly have access to a computer or tablet with an internet connection; have access to a desktop or laptop computer with an internet connection at least once every 6 months; ability to send and receive emails; ability to complete online assessments)\n* Sufficient vision to participate in an online educational program and complete online cognitive testing\n* Ages 50-80\n* Classified as being at increased risk of dementia based on at least one of the following:\n\n  * First-degree family history of dementia\n  * Education level at or below high school (grade 12 or less)\n  * Self-Reported: Hypertension, Hypercholesterolemia, Body Mass Index \\> 30 kg\u002Fm2 (derived from NIH Metric BMI Calculator), or Physical Inactivity (active is defined as engaging in a minimum of 20- 30 min of physical activity causing sweating and breathlessness, at least 2 times a week)\n\nExclusion Criteria:\n\n* Individuals who have a clinical diagnosis of Dementia (based on self-report)\n* Individuals who are currently participating in or have participated in a past study involving BHPro",{"count":517,"type":22},700,[151],"This study will recruit participants at risk for dementia to participate in an online educational program called Brain Health PRO (BHPro). The BHPro intervention is designed to address modifiable risk factors for dementia through a 6-month, fully online, educational program conveying the best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health. Achieving lifestyle changes in a diverse Canadian population through online education would be a major achievement in dementia prevention in Canada, with widespread personal and socioeconomic benefits.\n\nEligible participants will be randomly assigned to either start Brain Health PRO immediately or in 6 months (delayed-start control group). All participants will have the opportunity to have access to BHPro for 6 months during the course of the study and will have open access to all content for 12 months following the initial 6-month intervention. Participation will last from 18-24 months depending on group assignment.",[521,522,28,523,524,525],"Dementia Prevention","Subjective Cognitive Impairment","Cognitive Change","Lifestyle Intervention","Dementia Education",[527,528,529,530,531,380,532,533],"dementia education","at risk for dementia","lifestyle intervention","dementia reduction","dementia risk factor","cognitive impairment","Alzheimer risk","2026-05-14",{"date":502,"type":42},{"date":537,"type":42},"2026-05-07",{"date":187,"type":22},{"name":540,"class":49},"University of British Columbia",{"id":542,"slug":4,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":561},"100630287","NCT07485712","Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2","Center for Research and Education on Aging and Technology Enhancement - CREATE V","Inclusion Criteria:\n\n* 62+ years of age\n* Able to read English at the 6th grade level\n* Have 20\u002F60 vision with or without correction.\n* Clinical diagnosis of mild cognitive impairment (MCI)\n* Subjective cognitive complaints\n* Evidence by clinical evaluation\n* Clinical Dementia Rating Global scale of 0.5-2.0\n* Probable MCI\n* Montreal Cognitive Assessment (MoCA) score of 18-26\n* No major Instrumental activities of daily living (IADL) impairments\n* Geriatric Depression Scale of 4 or Below\n* No diagnosis of dementia\n\nExclusion Criteria:\n\n* Blind or have visual impairments that limit their ability to view the technology.\n* Deaf or have hearing impairments that limit their ability to answer telephone queries.\n* Have a life-limiting\u002Fterminal illness\n* Severe motor impairment (e.g., severe tremors or debilitating arthritis in their hands) that impairs ability to speak or use dominant hand\n* Cognitive impairment (MOCA ≤ 25)",{"count":548,"type":22},290,[151],"The goal of this Stage 1 (NIH Stage Model) Intervention Development cross-site project is to develop, using a user-centered design approach, and evaluate an innovative intelligent adaptive software package aimed at providing cognitive and social support and engagement to older adults with mild cognitive impairment (MCI). The system will be designed to adapt to the needs and abilities of the user. The investigator's goal is to develop a unique and highly innovative technology tool that can provide adaptive support to aging individuals with MCI, even as cognition might deteriorate further. Speech data collected as part of an embedded reminiscence feature will advance fundamental knowledge of how speech and language production data might serve as an early indicator of cognitive decline.",[28],[553],"Technology","2026-05-12",{"date":407,"type":42},{"date":557,"type":22},"2026-08-31",{"date":161,"type":22},{"name":560,"class":49},"Weill Medical College of Cornell University",3,{"id":563,"slug":4,"hasResults":11,"nctId":564,"briefTitle":565,"officialTitle":545,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":570,"conditions":571,"keywords":572,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":561},"100501598","NCT05811338","Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1","Inclusion Criteria:\n\n* 65+ years of age\n* Able to read English at the 6th grade level\n* Have 20\u002F60 vision with or without correction.\n\nExclusion Criteria:\n\n* Blind or have visual impairments that limit their ability to view the technology.\n* Deaf or have hearing impairments that limit their ability to answer telephone queries.\n* Have a life-limiting\u002Fterminal illness\n* Severe motor impairment (e.g., severe tremors or debilitating arthritis in their hands) that impairs ability to speak or use dominant hand\n* Chronic neck pain\u002Finjury that might make the headset uncomfortable",{"count":568,"type":22},312,[151],"Project 1: The goal of this research project is to examine usability and acceptance of virtual reality (VR) applications and their efficacy with older adults. This highly innovative cross-site Stage 1 Intervention Development Project (NIH (National Institutes of Health) Stage Model) will apply the CREATE systematic approach to the design and evaluation of an immersive VR program, Cognitive Activity Social Technology (CAST), for older adults. The program will provide a suite of virtual cognitive, social and activity engagement applications; and allow for virtual interactions.",[28],[553],{"date":407,"type":42},{"date":575,"type":22},"2026-07-31",{"date":161,"type":22},{"name":560,"class":49},{"id":579,"slug":4,"hasResults":11,"nctId":580,"briefTitle":581,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":286,"enrollmentInfo":583,"targetDuration":4,"studyType":23,"phases":584,"briefSummary":585,"conditions":586,"keywords":589,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":50},"100624989","NCT07416799","Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment","Inclusion Criteria:\n\n1. Age: 55-80 years\n2. Diabetes: Diagnosed T2DM with ≥5 years duration\n3. Cognitive Status: Mild cognitive impairment as defined by Petersen criteria and confirmed by Montreal Cognitive Assessment (MoCA) scores of 18-25\n4. Medication Stability: Stable medication regimen for at least 3 months\n5. Physical Capability: Physically capable of participating in moderate-intensity exercise (physician clearance required)\n6. Support System: Having a caregiver or support person willing to assist with technology use if needed\n\nExclusion Criteria:\n\n1. Diagnosis of movement disorders such as multiple sclerosis, parkinson's disease\n2. Diagnosis of Alzheimer's disease,\n3. Current diagnosis of severe depression, major psychiatric conditions such as bipolar disorder, psychosis, schizophrenia, or alcoholism that could affect the ability to understand and\u002For cooperate fully with the protocol.\n4. Significant cerebral vascular disease\n5. Concomitant medications with significant cholinergic or anticholinergic effects or adverse effects on cognition, including antipsychotics, tricyclic antidepressants, anticonvulsants, sedative\u002Fhypnotics, anxiolytics, glucocorticoids (chronic or frequent intermittent),\n6. Visual\u002Fhearing impairment that would significantly impact the ability to participate in psychometric testing.\n7. Significant medical illness or organ failure, including hepatic or renal failure, unstable cardiac disease,\n8. Untreated B12 deficiency or hypothyroidism (stable treatment for at least 3 months is allowable).\n9. Uncontrolled hypertension: over 160 mmHg systolic or 100 mmHg diastolic (stable treatment is allowable).\n10. Stage 5 renal impairment (GFR less than 15 or dialysis).\n11. Participation in another clinical trial.\n12. Prisoners.\n13. Exercise Contraindications: Any condition that would make moderate-intensity exercise unsafe such as a history of severe aortic stenosis, poorly controlled hypertension, angina, or syncope.\n14. Lack of Support: No available caregiver or support person for technology assistance",{"count":87,"type":22},[151],"This is a single-arm feasibility study employing a pre-post design with a 12-week intervention period. The study utilizes a telehealth-assisted home-based resistance exercise program, with a structured progression from supervised to unsupervised sessions over 12 weeks.",[587,28,588],"Type2diabetes","Age-related Cognitive Decline",[590,591,592,593],"Home-Based exercise","Type 2 Diabetes Mellitus (T2DM)","Mild cognitive impairment (MCI)","Ages 55-80",{"date":595,"type":42},"2026-05-11",{"date":597,"type":42},"2026-04-14",{"date":599,"type":22},"2027-03",{"name":601,"class":49},"The University of Texas Medical Branch, Galveston",{"id":603,"slug":4,"hasResults":11,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":286,"enrollmentInfo":608,"targetDuration":4,"studyType":23,"phases":609,"briefSummary":610,"conditions":611,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":612,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":50},"100512167","NCT05948930","Working Memory and Physical Exercise Training in Patients With Mild Cognitive Impairment","Adaptive Working Memory and Physical Exercise Training to Improve Brain and Mitochondrial Function in MCI","Inclusion Criteria:\n\n* Adult men and women of all races and ethnicities who are 50-80 years of age will be eligible.\n* Only sedentary adults will be eligible (engaging in structured activity for exercise \\\u003C3x\u002Fweek) for Progressive aerobic exercise or Combined training\n* Ability to use, and accessibility to, an iPad or computer is required for the Adaptive cognitive training and Combined training.\n* Fluent in English.\n* The diagnosis of MCI will first be confirmed at the screening evaluation using the clinical dementia rating (CDR) scale and the Montreal Cognitive Assessment (MoCA). We will also evaluate their ADL using instrumental activities of daily living (IADL) to ensure they have preserved independence in functional abilities despite the cognitive deficits. The primary caregivers will be interviewed (either in person or by phone) for the participants' IADL to corroborate the independent functional status.\n\nExclusion Criteria:\n\n* Does not have access to a computer or internet to perform the Cogmed® training AND is unwilling to come to the lab for the training.\n* Unable to undergo an MRI investigation based on claustrophobia or metal foreign bodies.\n* Symptomatic heart disease, Coronary artery disease, congestive heart failure, uncontrolled hypertension, uncontrolled diabetes (HbA1c\\>10%), significant cardiovascular disorders (on EKG and graded exercise test) that would prevent the participant from the exercise training; neurologic, musculoskeletal, or other condition that limits the subject's ability to complete study physical assessments.\n* Estimated verbal Intelligence Quotient (IQ) below 70 (based on the Wechsler Test of Adult Reading) which would invalidate the informed consent process for the study.\n* Self-reported moderate to severe substance use disorder(s) (e.g., self-reported intake \\>3 oz liquor, or three 4 oz glasses of wine, or three 12 oz cans of beer per day or illicit drug use).\n* Severe chronic or acute medical or other (non-MCI) neuropsychiatric conditions that might confound the cognitive or brain imaging measures (e.g., liver function tests \\>2.5 normal range or evidence for renal failure).\n* Body mass index \\>40 kg\u002Fm2.",{"count":60,"type":22},[151],"The prevalence of dementia will double in the next three decades in the U.S.; effective treatment or prevention for dementia is urgently needed. The current exploratory project aims to evaluate and understand how the brain and cognition may improve after a 12-week intervention that combines brain training and aerobic exercise training to improve brain function, both in those with mild cognitive impairment (some with possible prodromal Alzheimer's disease) and with healthy aging. Findings from this pilot project will guide and refine the development of a future larger clinical trial that aligns with the goals of the National Alzheimer's Plan of Action (NAPA), especially regarding \"Prevent and Effectively Treat Alzheimer's Disease (AD) by 2025.",[28],{"date":554,"type":42},{"date":614,"type":42},"2024-01-08",{"date":616,"type":22},"2027-08-07",{"name":618,"class":49},"University of Maryland, Baltimore",{"id":620,"slug":4,"hasResults":11,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":17,"sex":18,"minAge":217,"maxAge":120,"enrollmentInfo":625,"targetDuration":4,"studyType":23,"phases":627,"briefSummary":629,"conditions":630,"keywords":633,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":641,"locationsCount":50},"100557453","NCT06538311","Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease","Neuromodulation of Brain Function in Alzheimer's Disease and Related Dementias","Inclusion Criteria:\n\n1. Between the ages of 40-99\n2. Native English speakers\n3. Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points\n4. Patients with PPA will be asked to bring a study partner to all visits\n5. Patients with very mild or mild PPA, patients with amnestic mild cognitive impairment and cognitively unimpaired participants with preclinical AD will be included.\n\nExclusion Criteria:\n\n1. History of head trauma involving loss of consciousness or alteration in consciousness\n2. Another major neurologic or psychiatric condition\n3. Known presence of a structural brain lesion (e.g. tumor, cortical infarct)\n4. Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body\n5. Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed\n6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.\n7. Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging\n8. History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.).\n9. Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder.\n10. Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.\n11. Subjects actively on anti-amyloid treatments. This is because they are at risk for bleeding due to amyloid-related imaging abnormalities (ARIA) that could provoke seizures.",{"count":626,"type":22},30,[628],"EARLY_PHASE1","In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI).\n\nThis study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI).\n\nParticipants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.",[29,28,631,632],"Logopenic Progressive Aphasia","Amnestic Symptoms",[227],"2026-05-05",{"date":636,"type":42},"2026-05-06",{"date":638,"type":42},"2023-05-01",{"date":640,"type":22},"2027-03-31",{"name":642,"class":49},"Massachusetts General Hospital",""]